Deepak Patel, MD
Pulmonary Disease · Sebring, FLNPI 1821038852
Payments from drug & device makers
Across 541 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- Takeda Pharmaceuticals U.S.A., Inc.$914
- Insmed, Inc.$845
- Paratek Pharmaceuticals, Inc.$794
- Regeneron Healthcare Solutions, Inc.$683
- Grifols USA, LLC$639
- plus $6K from 51 others
What the payments were for
- Travel & lodging$1,44713%
- Food & beverage$9,70185%
- Education$2322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,381 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 21 | $1,377,577 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 42 | $628,208 |
| OfevNintedanib Esylate | 28 | $348,370 |
| OpsumitMacitentan | 20 | $250,515 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 309 | $250,501 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $128,132 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $88,158 |
| OzempicSemaglutide | 52 | $72,022 |
| XareltoRivaroxaban | 74 | $69,585 |
| Dupixent SyringeDupilumab | 17 | $67,395 |
| MounjaroTirzepatide | 46 | $50,850 |
| EliquisApixaban | 70 | $49,735 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $30,389 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $29,182 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $18,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $302 | $1,377,57721 claims |
| Insmed, Inc.Arikayce | $845 | $628,20842 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $462 | $381,79377 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $138 | $285,896375 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $511 | $250,51520 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $914 | $128,13212 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $566 | $101,760142 claims |
| Novo NordiskOzempic | $307 | $72,02252 claims |
| Johnson & JohnsonXarelto | $152 | $69,58574 claims |
| Lilly USA, LLCMounjaro | $240 | $50,85046 claims |
| PfizerEliquis | $13 | $49,73570 claims |
| MerckJanuvia, Belsomra | $229 | $25,93642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Sebring
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.